Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymyxin B | 1 | 2026 | 11 | 0.950 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2026 | 11 | 0.940 |
Why?
|
| Proteome | 6 | 2014 | 153 | 0.770 |
Why?
|
| Proteomics | 6 | 2014 | 299 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 807 | 0.610 |
Why?
|
| Blood Proteins | 2 | 2013 | 84 | 0.460 |
Why?
|
| Mass Spectrometry | 3 | 2014 | 296 | 0.410 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2011 | 9 | 0.410 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 5 | 2009 | 37 | 0.380 |
Why?
|
| Immunoassay | 1 | 2012 | 71 | 0.370 |
Why?
|
| Genes, APC | 2 | 2011 | 12 | 0.360 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 285 | 0.290 |
Why?
|
| Colon | 2 | 2007 | 148 | 0.280 |
Why?
|
| Piperazines | 1 | 2008 | 86 | 0.270 |
Why?
|
| Pyrimidines | 1 | 2008 | 144 | 0.260 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 170 | 0.240 |
Why?
|
| Acinetobacter Infections | 1 | 2026 | 7 | 0.240 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 290 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 644 | 0.190 |
Why?
|
| Proteins | 2 | 2007 | 764 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 161 | 0.140 |
Why?
|
| Isoelectric Focusing | 3 | 2012 | 13 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 250 | 0.130 |
Why?
|
| Mucins | 2 | 2014 | 27 | 0.120 |
Why?
|
| Middle Aged | 6 | 2026 | 18439 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2013 | 141 | 0.110 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 30 | 0.110 |
Why?
|
| Humans | 13 | 2026 | 65645 | 0.110 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 79 | 0.110 |
Why?
|
| Calgranulin A | 1 | 2014 | 5 | 0.100 |
Why?
|
| Calgranulin B | 1 | 2014 | 6 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 1172 | 0.100 |
Why?
|
| Male | 6 | 2026 | 31292 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2015 | 223 | 0.090 |
Why?
|
| Albumins | 1 | 2012 | 43 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2011 | 322 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2012 | 127 | 0.090 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2011 | 3 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 1715 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2011 | 34 | 0.080 |
Why?
|
| Registries | 1 | 2015 | 934 | 0.080 |
Why?
|
| Heterozygote | 1 | 2011 | 173 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 472 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 354 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 526 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2012 | 418 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 278 | 0.070 |
Why?
|
| Cyst Fluid | 1 | 2009 | 5 | 0.070 |
Why?
|
| Pancreatic Cyst | 1 | 2009 | 22 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 345 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2011 | 423 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 8 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 593 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 34 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 19 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 42 | 0.070 |
Why?
|
| Methotrexate | 1 | 2008 | 80 | 0.070 |
Why?
|
| Benzamides | 1 | 2008 | 69 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 588 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1144 | 0.070 |
Why?
|
| Catalase | 1 | 2007 | 22 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 38 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 216 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 707 | 0.060 |
Why?
|
| Stroke | 1 | 2015 | 1221 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 223 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 797 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 1573 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2011 | 1559 | 0.050 |
Why?
|
| Reference Standards | 2 | 2013 | 76 | 0.050 |
Why?
|
| Adult | 4 | 2015 | 17511 | 0.040 |
Why?
|
| Aged | 3 | 2015 | 15089 | 0.040 |
Why?
|
| Young Adult | 1 | 2011 | 4855 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 292 | 0.030 |
Why?
|
| Female | 4 | 2015 | 34309 | 0.030 |
Why?
|
| United States | 2 | 2020 | 8166 | 0.030 |
Why?
|
| Pancreatic Juice | 1 | 2014 | 1 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 37 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 31 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2013 | 29 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 202 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 36 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 128 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 214 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 235 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 420 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1265 | 0.020 |
Why?
|
| Trypsin | 1 | 2012 | 43 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 128 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 5656 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 69 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2012 | 194 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 377 | 0.020 |
Why?
|
| Stents | 1 | 2015 | 501 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1432 | 0.020 |
Why?
|
| Proteolysis | 1 | 2012 | 155 | 0.020 |
Why?
|
| Amylases | 1 | 2009 | 12 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 35 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 89 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 185 | 0.020 |
Why?
|
| Leucovorin | 1 | 2008 | 8 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 119 | 0.020 |
Why?
|
| Antidotes | 1 | 2008 | 15 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 58 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 63 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 89 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 267 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 199 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 205 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 611 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 253 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 995 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 319 | 0.010 |
Why?
|
| Cell Extracts | 1 | 2004 | 26 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 466 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1592 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 875 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 465 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3329 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 2670 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 6350 | 0.010 |
Why?
|